Researchers at Johns Hopkins have found that an old drug once mostly used to treat amebiasis -- a disease caused by a parasite -- and induce vomiting in cases of poisoning appears to also halt replication of cytomegalovirus (CMV), a herpesvirus that can cause serious disease in immunocompromised individuals, including those with HIV or organ transplant recipients.
A report on the finding, made in test tube and mice studies, is published in the June 23 PLOS Pathogens and could potentially offer a much-needed tool to inhibit CMV, the investigators say.
Most people worldwide permanently harbor CMV, which causes no symptoms in the healthy. However, for those with a challenged or compromised immune system, the virus can cause diseases affecting multiple organs, such as the liver gut, lungs and brain. CMV is also the most common congenital infection passed from mother to child, leading to significant birth defects, such as microcephaly, hearing loss and other neurodevelopmental problems.
A few drugs exist to treat CMV by inhibiting its replication in cells, but Ravit Boger, MD, associate professor of pediatrics and oncology at the Johns Hopkins University School of Medicine, says these medications are associated with problematic side effects, including toxicity to the bone marrow and kidneys. Additionally, resistant strains of CMV sometimes emerge during treatment, creating "a desperate need for other ways to control this virus," says Boger.
Recently, investigators started a strategic search for useful drugs by screening those already approved by the Food and Drug Administration (FDA) for new uses. Collaborating with Marc Ferrer at the National Institutes of Health, Boger screened a library of 1,280 such pharmacologically active compounds to see if any of these might inhibit CMV replication in laboratory cell cultures.
Testing each of these compounds in infected cells, the researchers found a "hit" with emetine, a drug that was used in the past to treat amebiasis before other drugs took its place decades ago.
Results from the study showed that much lower concentrations of emetine can inhibit CMV as compared to those used for amebiasis, and less frequent doses might be effective for CMV inhibition. Indeed, tests in infected cells in the laboratory and in live mice showed that very low doses of emetine significantly reduced viral replication in both of these models (75 nanomolar in test tube and 0.1 milligram per kilogram in mice). Additionally, with a long half-life of 35 hours, the drug exerted its effects over a sustained period, effectively inhibiting virus replication at 14 days after three doses.
Additional investigation performed by Johns Hopkins postdoctoral fellows Rupkatha Mukhopadhyay and Sujayita Roy revealed that emetine's action against the virus was due to its effects on cellular proteins that control the cell cycle.
Boger cautions that researchers still have a long way to go before emetine or similar agents that target protein interactions in the cell can be considered for treatment of CMV. No one yet knows what an effective low dose would be, what short- and long-term side effects might occur, and whether the drug would be safe for this use. However, old data from higher doses used for amebiasis are encouraging.
"But if further research affirms its potential value," she says, "emetine might eventually be used in patients who don't respond to approved anti-CMV drugs, alone or in combination with these." Additionally, she says, developing a better understanding of emetine's activity in cells could lead to discovery of new drugs that take advantage of the same or similar pathways.
Experts estimate that about 60 to 70 percent of adults in industrialized countries are infected with CMV, and nearly 100 percent of those in emerging countries carry this virus. Transmission is thought to occur mostly through bodily fluids. About one in 100 to 200 babies is born with this infection through mother-to-child transmission, making CMV the most common congenital infection, which takes a major toll on families.
Johns Hopkins researcher Yu-Pin Su also participated in this work.
Source: Johns Hopkins Medicine
Dear Helpdesk: Working in a Toxic Health Care Environment
March 28th 2024Dear Helpdesk is your steadfast companion, offering life coaching and workplace advice from 2 seasoned IPs for some of your most challenging real-life situations. Let us help you navigate the intersection between work and life, guiding you to navigate the dynamic world of infection prevention with confidence and grace. This article is on handling a toxic health care environment.
Product Locator: Spring and Early Mother's Day Gift Guide for Infection Prevention Personnel
March 27th 2024Whether it's a spring holiday, birthdays, or no reason at all, infection prevention personnel love to give and receive gifts that help at the end of a stressful day. Infection Control Today® offers some gift ideas for infection prevention personnel and their families.
Catching Up With Vangie Dennis, AORN 2022-2023 President at AORN 2024
March 26th 2024Infection Control Today (ICT) had the privilege of catching up with Vangie Dennis, MSN, RN, CNOR, CMLSO, at the Association of periOperative Registered Nurses' (AORN’s) International Surgical Conference & Expo 2024. As the former president of AORN and an esteemed figure in perioperative services, Vangie Dennis shared insights into her recent endeavors and the exciting new chapter she's embarked upon.
How To Optimize Your Time Management Strategies for the Busy Infection Preventionist
March 25th 2024Is your calendar resembling a chaotic masterpiece of overlapping tasks? Join the club of infection preventionists striving to balance responsibilities. Dive into proven strategies from a fellow infection preventionist to reclaim control of your time, streamline tasks, and boost productivity effectively. This is an IP Lifeline article.